Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy and lymphadenectomy for patients with early-stage, intermediate-risk cervical carcinoma indicated that the addition of chemotherapy did not improve outcomes for patients and led to increased toxicity for patients.
U.K., pharma industry strike deal for how the NHS pays for medicines
LONDON — The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as
November 20, 2023